OMX Nordic 40
|
2 714,19
|
3,98
|
0,15 %
|
Analysen zu OMX Nordic 40-Werten
| 12.11.24 | AstraZeneca Sell | UBS AG | |
| 12.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 12.11.24 | ABB Neutral | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 11.11.24 | Novo Nordisk Neutral | UBS AG | |
| 11.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 11.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 08.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 08.11.24 | Novo Nordisk Overweight | Barclays Capital | |
| 07.11.24 | Novo Nordisk Neutral | UBS AG | |
| 07.11.24 | Novo Nordisk Halten | DZ BANK | |
| 07.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 07.11.24 | AstraZeneca Sell | UBS AG | |
| 07.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.11.24 | Novo Nordisk Neutral | UBS AG | |
| 06.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 06.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 06.11.24 | Novo Nordisk Neutral | UBS AG | |
| 06.11.24 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 06.11.24 | AstraZeneca Hold | Deutsche Bank AG | |
| 06.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 05.11.24 | AstraZeneca Sell | UBS AG | |
| 05.11.24 | AstraZeneca Sell | Deutsche Bank AG | |
| 05.11.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 05.11.24 | Hennes & Mauritz AB Outperform | RBC Capital Markets | |
| 05.11.24 | AstraZeneca Buy | Goldman Sachs Group Inc. | |
| 04.11.24 | AstraZeneca Sell | UBS AG | |
| 04.11.24 | Novo Nordisk Neutral | UBS AG | |
| 04.11.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 04.11.24 | ABB Neutral | Goldman Sachs Group Inc. | |
| 04.11.24 | Novo Nordisk Buy | Goldman Sachs Group Inc. | |
| 04.11.24 | AstraZeneca Overweight | JP Morgan Chase & Co. | |
| 01.11.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 31.10.24 | Novo Nordisk Buy | Deutsche Bank AG | |
| 31.10.24 | A.P. Moeller - Maersk A-S Neutral | UBS AG | |
| 30.10.24 | Novo Nordisk Overweight | JP Morgan Chase & Co. | |
| 29.10.24 | ABB Neutral | JP Morgan Chase & Co. | |
| 29.10.24 | ABB Neutral | Goldman Sachs Group Inc. | |
| 28.10.24 | Novo Nordisk Neutral | UBS AG | |
| 28.10.24 | Hennes & Mauritz AB Underweight | JP Morgan Chase & Co. |